RECORD OF TELEPHONE CONVERSATION

Submission Information

Application Type	BLA
STN	125606/0.0
Review Office	OTAT
Applicant	CSL Behring GmbH / Lic. # 1765
Product	C1 Esterase Inhibitor Subcutaneous (Human)
Trans-BLA Group:	No

Telecon Details

Telecon Date/Time	22-FEB-2017 02:15 PM
Author	CAGUNGUN, NANNETTE
EDR	No
Post to Web	No
Outside Phone Number	
FDA Originated?	No
Communication Categories	OT -
Related STNs	None
Related PMCs	None
Telecon Summary	Clarification sought by CSLB on Clinical Pharmacology IR dated 2/13/17.
FDA Participants	Iftekhar Manhood, Nannette Cagungun

RECORD OF TELEPHONE CONVERSATION

Applicant Participants	• Hartmut Landgrebe, PhD Director Global Regulatory Affairs, Therapeutic Area Lead Critical Care Development Products • Dipti Pawaskar, PhD Associate Director Clinical Pharmacology and Clinical Pharmacology Early Development • Mike Tortorici, PhD Director, Clinical Pharmacology, Pharmacometrics and Clinical Pharmacology Early Development • Iris Jacobs, MD, Senior Global Clinical Program Director • Ingo Pragst, DVM, PhD Global Clinical Program Director • John-Philip Lawo, Director Biostatistics, Therapeutic Area Lead • Henrike Feuersenger, PhD Senior Statistical Scientist, Immunology and Inflammation • Michele Walsh, Regulatory Manager

Telecon Body:

CSL Behring requested this telecon to seek clarification for the February 13, 2017 information request which contained the following items:

Study # CSL 830-1001

1. Please explain the reason for not calculating AUC(0-inf) for most of the subjects. Please calculate clearance based on AUC(0-last) for all subjects (only for CSL-830) by functional activity.

Discussion:
CSLB agreed to calculate clearance based on AUC (0-last) and will submit the data by March 7, 2017. FDA agreed.

Study # CSL 830-2001

In Table 9.3, you mentioned that C1-INH functional activity was measured at several time points. However, you also mentioned in section 9.5.4 that Plasma concentrations of CSL830 were not measured in this study. Functional activity can also be interpreted as concentrations.

2. From Table 9.3 it appears that you have several functional activities of CSL830 over time. From these time points, please calculate the PK parameters for all subjects (3 subjects rescued can be omitted from the study) using non-compartmental analysis.

3. In a Tabulated form (in a single Table) please provide subject ID, body weight, age and gender along with PK parameters of CSL 830 (Cmax, AUC, Clearance, Volume of distribution, and half-life) estimated by non-compartmental analysis.

4. In a separate Table, please provide the functional activities at time points you measured these activities in each subject for studies CSL830-2001 and CSL830-3001.

Discussion:

CSLB explained their rationale for not using non-compartmental analysis. FDA will not require further analysis.

With regard to item 4, CSLB will provide the requested data by February 28, 2017. FDA agreed.